Will the sales director of Novo Nordisk protest due to emotional disputes? Company response: Personal dispute
白云追月素
发表于 2023-11-26 09:13:32
274
0
0
Recently, a video of Cheng, the sales director of Novo Nordisk China, being protested by a woman in red at an academic conference has been circulating online, causing heated discussions. Afterwards, Novo Nordisk replied to the media that it was "completely a personal dispute among employees.".
According to the online video, on November 23, at the branch venue of the 25th National Academic Conference of the diabetes Branch of the Chinese Medical Association held in Wuhan International Conference Center, a woman in red held a microphone and shouted about her emotional dispute with a member of Novo Nordisk Project, and was immediately invited out of the venue by the conference staff.
On the afternoon of November 24th, a staff member of the Enterprise Exchange Department of Novo Nordisk confirmed to the media that Mr. Cheng is an employee of the company and the Sales Director of the South China region. He stated that "it is completely a personal dispute among employees, and our company will continue to pay attention and further understand the situation.".
Another online email screenshot shows that it is suspected that the woman claimed to have evidence in an internal email of the company, intending to expose the issue of Mr. Cheng. On the evening of the 23rd, a 113 page document was sent out, accusing Mr. Cheng of deceiving the company and "uncovering the glamorous veil of Mr. Cheng from Novo Nordisk.". It is reported that there have been relevant documents circulating online before.
Netizens also posted an email response suspected of Mr. Cheng, with screenshots showing that the email stated that Mr. Cheng had been "extorted" a huge sum of money seven years ago. Four years ago, he sued the woman in court and announced in July this year that she had become a "deadbeat". The email also stated that the parties involved will "report a criminal case and request IT to block their email.".
Public information shows that Novo Nordisk was founded in 1923 and is a leading global biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. The goal of the enterprise is to promote change to overcome diabetes and obesity, rare blood diseases, endocrine disorders and other serious chronic diseases. Novo Nordisk has approximately 47000 employees in 80 countries and regions worldwide, providing products and services to over 168 countries and regions worldwide.
Since the beginning of this year, the so-called "weight loss miracle drug" Smeglutai has gone viral, causing the stock price of Novo Nordisk to skyrocket. On November 24th, Novo Nordisk's stock price rose 2.12% to close at $105.45 per share, setting a new historical closing high. Novo Nordisk's stock price has risen by 4.00% this week, and has been rising for four consecutive weeks. On the news front, Novo Nordisk stated in a statement that it plans to invest 2.1 billion euros (2.3 billion US dollars) to expand production in France to meet the growing demand for its popular weight loss medication.
According to the financial report, Novo Nordisk achieved sales revenue of DKK 166.398 billion in the first three quarters of this year, a year-on-year increase of 29%; The net profit was 61.72 billion Danish kroner, a year-on-year increase of 47%. From the product perspective, the GLP-1 inhibitor Smegglutide has achieved significant growth.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Xiaopeng Automotive's Director of Autonomous Driving Resigns? The response is coming
- Tesla's German factory faces nearly a thousand people protesting! Oppose expansion
- US cybersecurity chief criticizes CrowdStrike update flaw: This is a serious mistake
- Dada Group: Guo Qing replaces Dan Su as Chairman of the Board of Directors
- Xiaopeng Motors Chairman Talks about Autonomous Driving: Expected to Enable Everyone to Drive Like Experienced Drivers in the Next Three Years
- Novo Nordisk reaches settlement with Mylan Pharmaceuticals over patent dispute over weight loss drug Ozempic and Wegovy
- SAIC General Motors completes industrial and commercial changes, Zhuang Jingxiong resigns as director and general manager
- ARM plans to cancel license for Qualcomm chips, intensifying dispute between two parties
- Has Ralph Lauren achieved a 95% return rate as a "miracle tool" for order stuffing? Tmall PR Director responds
- TSMC director claims Qatar invited company to set up factory
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 2 小时前
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏